Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Protean Small Cap. This analysis is provided for institutional research purposes only and is not investment advice.
"Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment company shorts."
Protean Funds' September 2025 letter discusses a flat-to-negative month (Protean Small Cap -1.4%, Protean Select -1.2%) in a muted Nordic market environment. The team details their strategy of 'grinding it out' through active adjustments and nimbleness, rejecting the passive 'long-term' justification for underperformance. Key portfolio movements include building up beaten-down MedTech exposures (such as Demant, Coloplast, Elekta, Chemometec, and Devyser), which represent 18% of the fund. They present a deep-dive thesis on Getinge, arguing the stock could double simply by avoiding errors and normalizing quality assurance costs. Additionally, the fund added Electrolux Professional and Eastnine to its holdings, while successfully wrapping up a profitable short trade in Swedish investment companies.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Growth Outlook
Market outlook remains moderate conviction: Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Risk Appetite
Risk appetite posture is above average conviction: Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Forward Guidance
Forward guidance signal: Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Language Signal
Tone analysis indicates above average conviction language: Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
Time Horizon
Investment time horizon reflects a above average conviction orientation. Protean embraces a 'grinder' mindset during a flat month, actively scaling into beaten-down Nordic MedTech names like Getinge and Devyser while closing out profitable investment co...
